Long-term outcomes of trimodality treatment for squamous cell carcinoma of the esophagus with cisplatin and/or 5-FU: More than 20 years’ experience at a single institution;Langzeitergebnisse der trimodalen Therapie des Ösophagusplattenepithelkarzinoms mit Cisplatin und/oder 5-FU: Mehr als 20 Jahre Erfahrung an einem einzigen Institut

Strahlentherapie und Onkologie

Volumn 190, Issue 12, 2014, Pages 1133-1140

  Fakhrian, Khashayar ^a,b   Ordu, Arif Deniz ^b   Lordick, Florian ^c,d   Theisen, Jörg ^b   Haller, Bernhard ^b   Omrčen, Tomislav ^b,e   Molls, Michael ^b   Nieder, Carsten ^f   Geinitz, Hans ^b,g  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e UNIVERSITY HOSPITAL SPLIT   (Croatia)

^f UNIVERSITY OF TROMSØ   (Norway)

^g Krankenhaus der Barmherzigen Schwestern Linz   (Austria)

Author keywords

Cisplatin; Esophagus; Fluorouracil; Squamous cell carcinoma; Trimodality treatment

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE; FLUOROURACIL; OXALIPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BRONCHOSCOPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURGERY; CANCER SURVIVAL; CANCER SURVIVOR; CHEMORADIOTHERAPY; DISEASE FREE SURVIVAL; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; FOLLOW UP; HEAD AND NECK CANCER; HEART ARREST; HUMAN; INDUCTION CHEMOTHERAPY; LONG TERM CARE; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORPHOMETRICS; MORTALITY; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIOPERATIVE PERIOD; PNEUMONIA; RADIATION DOSE; RADICAL RESECTION; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR LOCALIZATION; WEIGHT REDUCTION; ADJUVANT CHEMORADIOTHERAPY; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; LONGITUDINAL STUDY; PATHOLOGY; PROCEDURES; SURVIVAL RATE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY, ADJUVANT; CISPLATIN; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; LONGITUDINAL STUDIES; MALE; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84911808062     PISSN: 01797158     EISSN: 1439099X     Source Type: Journal    
DOI: 10.1007/s00066-014-0711-4     Document Type: Article

References (35)

1. Dubecz A, Gall I, Solymosi N et al (2012) Temporal trends in long-term survival and cure rates in esophageal cancer: a SEER database analysis. J Thorac Oncol 7:443–447
2. Enzinger PC, Mayer RJ (2003) Esophageal cancer. N Engl J Med 349:2241–2252
3. Parker EF, Gregorie HB (1976) Carcinoma of the esophagus, long-term results. JAMA 235:1018–1020
4. Smithers DW (1957) The treatment of carcinoma of the oesophagus. Ann R Coll Surg Engl 20:36–49
5. Watson WL, Pool JL (1948) Cancer of cervical esophagus: discussion of treatment. Surgery 23:893–905
6. Mariette C, Piessen G, Lamblin A et al (2006) Impact of preoperative radiochemotherapy on postoperative course and survival in patients with locally advanced squamous cell oesophageal carcinoma. Br J Surg 93:1077–1083
7. Berger AC, Farma J, Scott WJ et al (2005) Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol 23:4330–4337
8. Van Hagen P, Hulshof MC, van Lanschot JJ et al (2012) Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366:2074–2084
9. Tepper J, Krasna MJ, Niedzwiecki D et al (2008) Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 26:1086–1092
10. Kranzfelder M, Schuster T, Geinitz H et al (2011) Meta-analysis of neoadjuvant treatment modalities and definitive non-surgical therapy for oesophageal squamous cell cancer. Br J Surg 98:768–783
11. Urschel JD, Vasan H (2003) A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery with surgery alone for resectable esophageal cancer. Am J Surg 185:538–543
12. Fiorica F, Di Bona D, Schepis A et al (2004) Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut 53:925–930
13. Malthaner RA, Wong R, Rumble RB (2004) Neoadjuvant or adjuvant therapy for respectable esophageal cancer: a systematic review and meta-analysis. BMC Med 2:35–51
14. Gebski V, Burmeister B, Smithers BM et al (2007) Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 8:226–234
15. Greer SE, Goodney PP, Sutton JE et al (2005) Neoadjuvant chemoradiotherapy for esophageal carcinoma: a meta-analysis. Surgery 137:172–177
16. Lordick F, Hölscher AH, Haustermans K et al (2013) Multimodal treatment of esophageal cancer. Langenbecks Arch Surg 398:177–187
17. Bedenne L, Michel P, Bouché O et al (2007) Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 25:1160–1168
18. Brücher BL, Stein HJ, Zimmermann F et al (2004) Responders benefit from neoadjuvant radiochemotherapy in esophageal squamous cell carcinoma: results of a prospective phase-II trial. Eur J Surg Oncol 30:963–971
19. Lorenzen S, Brücher B, Zimmermann F et al (2008) Neoadjuvant continuous infusion of weekly 5-fluorouracil and escalating doses of oxaliplatin plus concurrent radiation in locally advanced oesophageal squamous cell carcinoma: results of a phase I/II trial. Br J Cancer 99:1020–1026
20. Stahl M, Stuschke M, Lehmann N et al (2005) Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 23:2310–2317
21. Fakhrian K, Ordu AD, Haller B et al (2014) Cisplatin- vs. oxaliplatin-based radiosensitizing chemotherapy for squamous cell carcinoma of the esophagus: a comparison of two preoperative radiochemotherapy regimens. Strahlenther Onkol (Epub ahead of print)
22. Brücher BL, Becker K, Lordick F et al (2006) The clinical impact of histopathologic response assessment by residual tumor cell quantification inesophageal squamous cell carcinomas. Cancer 106(10):2119–2127
23. Ott K, Lordick F, Molls M et al (2009) Limited resection and free jejunal graft interposition for squamous cell carcinoma of the cervical oesophagus. Br J Surg 96:258–266
24. Sobin LH, Wittekind C (eds); UICC International Union Against Cancer (2002) Esophagus (ICD-O C15). TMN classification of malignant tumors, 6th ed. Wiley-Liss, New York
25. Becker K, Mueller JD, Schulmacher C et al (1999) Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 85:1484–1489
26. Ancona E, Ruol A, Santi S et al (2001) Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone. Cancer 91:2165–2174
27. Lv J, Cao XF, Zhu B et al (2009) Effect of neoadjuvant chemoradiotherapy on prognosis and surgery for esophageal carcinoma. World J Gastroenterol 15:4962–4968
28. Fakhrian K, Oechsner M, Kampfer S (2013) Advanced techniques in neoadjuvant radiotherapy allow dose escalation without increased dose to the organs at risk. Strahlenther Onkol 189:293–300
29. Fakhrian K, Gamisch N, Schuster T et al (2012) Salvage radiotherapy in patients with recurrent esophageal carcinoma. Strahlenther Onkol 188(2):136–142
30. Semrau R, Herzog SL, Vallböhmer D et al (2012) Radiotherapy in elderly patients with inoperable esophageal cancer. Is there a benefit? Strahlenther Onkol 188(3):226–232
31. Lee JL, Park SI, Kim SB (2004) A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma. Ann Oncol 15:947–954
32. Orringer MB, Marshall B, Chang AC et al (2007) Two thousand transhiatal esophagectomies changing trends, lessons learned. Ann Surg 246:363–374
33. Wright CD, Kucharczuk JC, O’Brien SM et al (2009) Predictors of major morbidity and mortality after esophagectomy for esophageal cancer: a Society of Thoracic Surgeons General Thoracic Surgery Database risk adjustment model. J Thorac Cardiovasc Surg 137:587–596
34. Merritt RE, Whyte RI, D’Arcy NT et al (2011) Morbidity and mortality after esophagectomy following neoadjuvant chemoradiation. Ann Thorac Surg 92:2034–2340
35. Hurmuzlu M, Øvrebø K, Wentzel-Larsen T et al (2010) High-dose preoperative chemoradiotherapy in esophageal cancer patients does not increase postoperative pulmonary complications: correlation with dose–volume histogram parameters. Radiother Oncol 97:60–64